Vela Diagnostics Sequencing System for HIV-1 Genotype Testing

The Defense Health Agency (DHACA) plans to award a Firm Fixed Price, sole‑source contract to Vela Diagnostics, USA Inc. for provision of the Sentosa SQ Next Generation Sequencing system, associated reagent kits, consumables, maintenance, and repair services to support FDA‑approved HIV‑1 genotype testing at the Walter Reed Army Institute of Research. The award will be made via a reagent‑rental agreement; no competitive solicitation is being issued. Interested parties may submit capability statements by the indicated deadline, after which the contract will be awarded to Vela if no suitable alternatives are identified. • Supplies: Sentosa sequencer kits, consumables, sequencing system hardware, sub‑components, and maintenance/repair services. • Contract type: Firm Fixed Price, sole‑source, reagent rental agreement. • Deadline for capability statements: 27 August 2026, 10:00 AM EDT. • Primary point of contact: Brenda Mena (email provided).